-
- Mark Roschewski
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
-
- Michail S. Lionakis
- Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
-
- Jeff P. Sharman
- Willamette Valley Cancer Institute and Research Center, US Oncology, Eugene, OR, USA.
-
- Joseph Roswarski
- Hematology-Oncology Department, Walter Reed National Military Medical Center, Bethesda, MD, USA.
-
- Andre Goy
- John Theurer Cancer Center, Hackensack Meridian and School of Medicine at Seton Hall, NJ, USA.
-
- M. Andrew Monticelli
- Rocky Mountain Cancer Center, US Oncology, Colorado Springs, CO, USA.
-
- Michael Roshon
- Department of Emergency Medicine, Penrose-St. Francis Health Services, Colorado Springs, CO, USA.
-
- Stephen H. Wrzesinski
- Department of Medicine, St. Peter’s Hospital and US Oncology, Albany, NY, USA.
-
- Jigar V. Desai
- Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
-
- Marissa A. Zarakas
- Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
-
- Jacob Collen
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
-
- Keith M. Rose
- John Theurer Cancer Center, Hackensack Meridian and School of Medicine at Seton Hall, NJ, USA.
-
- Ahmed Hamdy
- Acerta Pharma, South San Francisco, CA, USA.
-
- Raquel Izumi
- Acerta Pharma, South San Francisco, CA, USA.
-
- George W. Wright
- Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD, USA.
-
- Kevin K. Chung
- Department of Medicine, St. Peter’s Hospital and US Oncology, Albany, NY, USA.
-
- Jose Baselga
- AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA.
-
- Louis M. Staudt
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
-
- Wyndham H. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
説明
<jats:p>Acalabrutinib targets activated BTK in macrophages and was associated with reduced inflammation and clinical improvement in COVID-19.</jats:p>
収録刊行物
-
- Science Immunology
-
Science Immunology 5 (48), eabd0110-, 2020-06-26
American Association for the Advancement of Science (AAAS)
